Danaher Corporation $DHR Stock Position Decreased by Howland Capital Management LLC

Howland Capital Management LLC reduced its position in shares of Danaher Corporation (NYSE:DHR) by 4.4% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 166,298 shares of the conglomerate’s stock after selling 7,662 shares during the quarter. Danaher makes up 1.3% of Howland Capital Management LLC’s investment portfolio, making the stock its 17th largest holding. Howland Capital Management LLC’s holdings in Danaher were worth $36,910,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. acquired a new position in Danaher during the 2nd quarter worth $10,492,520,000. Wellington Management Group LLP boosted its holdings in Danaher by 10.4% during the second quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate’s stock valued at $3,108,031,000 after acquiring an additional 1,542,310 shares during the period. Jupiter Topco LLC acquired a new stake in shares of Danaher in the second quarter valued at about $1,456,317,000. Generation Investment Management LLP acquired a new stake in shares of Danaher in the second quarter valued at about $1,287,949,000. Finally, Bank of America Corp DE bought a new position in shares of Danaher in the second quarter worth about $993,846,000. Institutional investors own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on DHR. Stifel Nicolaus raised their target price on Danaher from $220.00 to $260.00 and gave the company a “buy” rating in a report on Thursday. Evercore reiterated an “outperform” rating and set a $230.00 price target on shares of Danaher in a report on Monday, July 6th. Guggenheim increased their price objective on Danaher from $200.00 to $250.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. Royal Bank Of Canada raised their price objective on shares of Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a research note on Monday, October 5th. Finally, Morgan Stanley boosted their target price on shares of Danaher from $220.00 to $240.00 and gave the stock an “overweight” rating in a research report on Monday, October 12th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $242.91.

Danaher News Summary

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher reported third-quarter adjusted earnings of $2.11 per share, ahead of the $1.92 analyst consensus, while revenue increased 8.3% year over year to $6.55 billion. Biotechnology profitability and improving demand across several end markets supported the earnings beat. Danaher Beats Profit Estimates, Raises Outlook as Customer Demand Improves
• Positive Sentiment: Management raised its full-year 2026 adjusted EPS outlook to $8.57-$8.62, and biotechnology orders grew at a mid-teens rate. The company also highlighted margin expansion, improving customer demand, and artificial-intelligence capabilities that could support longer-term drug-discovery growth. Danaher: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Several analysts raised their price targets, including TD Cowen and JPMorgan to $270, Goldman Sachs to $275, and Stifel to $260. The upgrades reflect confidence in the earnings beat, improved execution, and the stronger profit outlook.
• Neutral Sentiment: New CEO Julie Montgomery emphasized the need to improve execution and innovation. Investors are watching whether management can convert the company’s AI and biotechnology investments into sustained growth. Danaher Posts First Earnings Under New CEO
• Negative Sentiment: Revenue was approximately in line with, or slightly below, estimates, while analysts cited tariff pressure and a cautious 2027 outlook. At roughly 41 times earnings, Danaher’s valuation leaves limited room for operational disappointment, contributing to the negative investor reaction despite the quarterly beat.

Danaher Stock Performance

Shares of NYSE DHR opened at $229.86 on Friday. The firm has a market capitalization of $161.59 billion, a price-to-earnings ratio of 40.83, a PEG ratio of 2.95 and a beta of 0.76. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80. The business has a fifty day simple moving average of $215.76 and a 200 day simple moving average of $197.12. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share for the quarter, topping analysts’ consensus estimates of $1.92 by $0.19. Danaher had a net margin of 16.91% and a return on equity of 11.22%. The firm had revenue of $6.55 billion for the quarter, compared to the consensus estimate of $6.56 billion. During the same quarter in the previous year, the company earned $1.89 earnings per share. The business’s revenue was up 8.3% compared to the same quarter last year. Sell-side analysts expect that Danaher Corporation will post 8.51 EPS for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.40 per share. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. Danaher’s dividend payout ratio (DPR) is currently 28.42%.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.